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Legionella pneumonia in the Niagara
Region, Ontario, Canada: a case series
Stephanie Cargnelli1, Jeff Powis2 and Jennifer L. Y. Tsang1,3*
Abstract
Background: Legionella pneumophila, a major cause of Legionnaires’ disease, accounts for 2–15 % of all community-
acquired pneumonia requiring hospitalization and up to 30 % of community-acquired pneumonia requiring intensive
care unit admission. Early initiation of appropriate antimicrobial therapy is a crucial step in the prevention of morbidity
and mortality. However, recognition of Legionnaires’ disease continues to be challenging because of its nonspecific
clinical features. We sought to describe hospitalized community-acquired Legionnaires’ disease to increase awareness
of this important and potentially lethal disease.
Methods: A retrospective multicenter observational study was conducted with all patients with confirmed Legionnaires’
disease in the Niagara Region of the Province of Ontario, Canada, from June to December 2013.
Results: From June to December 2013, there were 14 hospitalized cases of Legionnaires’ disease in the Niagara Region.
Of these, 86 % (12 patients) had at least one comorbidity and 71 % (10 patients) were cigarette smokers. In our cohort,
Legionnaires’ disease was diagnosed with a combination of a urinary Legionella antigen test and a Legionella real-time
polymerase chain reaction assay. Delay in effective antimicrobial therapy in the treatment of Legionella infection
led to clinical deterioration. The majority of patients had met systemic inflammatory response syndrome criteria
with fever >38 °C (71 %), heart rate >90 beats per minute (71 %), and respiratory rate >20 breaths per minute
(86 %). Eleven patients (79 %) required admission to the intensive care unit or step-down unit, and nine patients
(64 %) required intubation. Clinical improvement after initiation of antimicrobials was protracted.
Conclusions: Legionnaires’ disease should be considered during the late spring and summer months in patients
with a history of tobacco use and various comorbidities. Clinically, patients presented with severe, nonspecific,
multisystem disease characterized by shortness of breath, abnormal vital signs, and laboratory derangements
including hyponatremia, elevated creatine kinase, and evidence of organ dysfunction. In addition, antimicrobial
therapy with newer macrolides or respiratory fluoroquinolones should be initiated for severe community-acquired
pneumonia requiring intensive care unit admission, prior to laboratory confirmation of diagnosis, especially when
a clinical suspicion of Legionella infection exists.
Keywords: Legionella pneumophila, Legionnaires’ disease, Community-acquired pneumonia
Background
Legionella pneumophila, a gram-negative bacteria and the
main causative agent of legionellosis, was first recognized
in 1976 [1]. Legionellosis has two distinct clinical presenta-
tions: (1) Pontiac fever, a self-limited, febrile, flulike illness;
and (2) Legionnaires’ disease. Legionnaires’ disease is an
atypical pneumonia that has clinical and radiographic find-
ings similar to those of pneumococcal pneumonia [2–6]. It
has an incubation period of 2–14 days. Patients might
present with fever, cough, myalgia, asthenia, anorexia, and
relative bradycardia [2]. Symptoms that are more suggestive
of Legionnaires’ disease include gastrointestinal symptoms
(diarrhea, nausea, vomiting, and abdominal pain) and
neurologic symptoms (headache, obtundation, seizures, and
focal neurologic findings) [2, 7–10]. Legionnaires’ disease is
also characterized by nonspecific laboratory findings such
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as hyponatremia; hypophosphatemia; leukocytosis with
relative lymphopenia; elevated creatine kinase, erythrocyte
sedimentation rate, C-reactive protein, and ferritin levels;
myoglobulinuria; and microscopic hematuria [2].
Legionnaires’ diseases accounts for 2–15 % of hospital-
ized community-acquired pneumonia (CAP) and up to
30 % of CAP requiring intensive care unit (ICU) admis-
sion [11, 12]. The incidence of Legionnaires’ disease rose
by 192 % in the United States between 2000 and 2009 to
11.5 cases per 1 million population [13]. Sixty-two percent
of the cases occur in the summer and autumn seasons.
This is due to the increased use of air-conditioning sys-
tems and cooling towers as well as to increased rainfall
[14, 15]. Approximately 20 % of cases were travel-
associated [16]. Only 4 % of cases were associated with a
known outbreak [2]. The risk factors for Legionnaires’ dis-
ease include cardiopulmonary disease, cigarette smoking,
age >50 years, diabetes, malignancy, and immunosuppres-
sive state including glucocorticoid use [11, 17].
Legionnaires’ disease causes significant morbidity and
carries a mortality rate of 8–12 % [18]. Among patients
who survive, recovery is often slow, and they are left
with fatigue, neurologic and neuromuscular symptoms,
and post-traumatic stress disorder [19]. Legionnaires’
disease is also very costly, with a healthcare-associated
cost of more than $23,000 per case [20].
The diagnosis of Legionnaires’ disease can be made
using non-culture- and culture-based techniques [2]. A
urinary antigen test that detects a component of the cell
wall lipopolysaccharide is the first-line diagnostic test for
Legionnaires’ disease [21, 22]. However, it detects only L.
pneumophila serogroup 1, which is the most virulent
and most common cause of disease [11, 22, 23]. In
Europe, >90 % of Legionnaires’ disease cases were diag-
nosed by urinary antigen detection [2]. It is a rapid
test (results available within hours), with a sensitivity
of 56–99 % [22], and it is positive within 48–72 h of
symptom onset and can remain positive for several
weeks or months despite treatment [21, 22]. In addition to
urinary antigen detection, molecular tests such as a real-
time polymerase chain reaction (PCR) assay that targets
the 23S-5S ribosomal RNA (rRNA) intergenic spacer
region can be used for rapid detection, and this test has
the capability of differentiating L. pneumophila from 50
non-L. pneumophila species [24].
The isolation of Legionella bacteria by culture of the
lower respiratory tract using buffered charcoal yeast ex-
tract (BCYE) medium is still the gold standard for de-
tecting Legionnaires’ disease [22] because it allows the
diagnosis of all Legionella species, outbreak investiga-
tion, further epidemiologic studies, and antimicrobial
susceptibility testing [2]. However, culture of Legionella
is very cumbersome and technically demanding, and the
sensitivity is only around 20–80 % [2, 22].
Legionella species are intracellular pathogens; there-
fore, antibiotics should accumulate and be bioactive
within the cells [2]. Azithromycin, doxycycline, or levo-
floxacin can be considered as first-line therapy [2]. It is
recommended that levofloxacin 750 mg daily for 5–10
days or azithromycin 500 mg daily for 3–5 days be used
in patients with Legionnaires’ disease, except for patients
with immunosuppression, severe disease, empyema, and
extrapulmonary infection, as well as those undergoing
inappropriate initial therapy, for whom an extended
course is recommended [25–28]. Early initiation of ap-
propriate therapy is important in reducing mortality as-
sociated with Legionnaires’ disease [2, 29, 30].
In the summer of 2013, there were 14 hospitalized
cases of Legionnaires’ disease in the Niagara Region of
the Province of Ontario, Canada. The primary aim of
this study was to describe these14 cases of hospitalized
community-acquired Legionnaires’ disease to increase




We conducted a multicenter retrospective observational
study of all patients with hospitalized Legionnaires’ disease
in the Niagara Region of the Province of Ontario, Canada,
between June and December 2013. Legionnaires’ disease
was defined as a positive urinary Legionella antigen assay
result in the presence of symptoms or Legionella real-time
PCR of sputum or bronchoalveolar lavage (BAL) (both
performed in the Public Health Ontario Laboratory). The
urinary Legionella antigen assay was performed using a
commercial Binax immunochromatographic test kits
(Alere, Orlando, FL, USA) [31]. The results were reported
as positive or negative. The Binax test has >70 % sensitiv-
ity and >99 % specificity for L. pneumophila serogroup 1
only [31]. The real-time PCR assay used in this study tar-
gets the 23S-5S rRNA intergenic spacer region. It has the
ability to differentiate L. pneumophila from 50 other non-
L. pneumophila species. The detailed protocol was
described elsewhere [24]. All positive real-time PCR sam-
ples were cultured and identified to the genus, species,
and serogroup levels using BCYE and buffered polymyx-
ine B, anisomycin, and vancomycin charcoal media. The
plates were reincubated at 35 °C for up to 14 days and
examined under a microscope daily for colonial morph-
ology such as mottled surface and iridescent red-blue-green
sheen or a faceted cut-glass appearance. Slide agglutination
testing was used to speciate and serogroup L. pneumophila
isolates and atypical Legionella-like isolates. Known
antibodies were mixed with culture isolates on a glass
microscope slide. Antibodies against 50 Legionella spe-
cies/serogroup targets were used for this method on
the basis of the protocol developed by the Centers for
Cargnelli et al. Journal of Medical Case Reports  (2016) 10:336 Page 2 of 7
Disease Control and Prevention in the United States
[32]. Agglutination reactions were scored on a scale
from 4+ (strongest) to 1+ (barely visible). In cases of
cross-reaction (two or more species/serogroup targets
reactive), results were compared against specific posi-
tive and negative controls. The strongest reaction was
considered the final result.
Data collection
Our data collection form encompassed demographic
data, epidemiologic data, medical history, symptoms,
vital signs, and laboratory test results at admission.
We also recorded daily laboratory test results, anti-
microbial therapy information, and clinical outcome
data when available. Data collection was conducted at
three sites of Niagara Health where cases occurred,
including the St. Catharines sites, the Greater Niagara
General Hospital site, and the Welland site. Data col-
lection was performed using electronic medical re-
cords (Meditech, Westwood, MA, USA; IMPAX, Agfa
Health Care, Greenville, SC, USA) and paper medical
charts. Approval with a waiver of informed consent




From June 2013 to December 2013, there were a total of
14 hospitalized Legionnaires’ disease cases identified in
the Niagara Region of Ontario, Canada. These contrib-
uted to approximately 2 % of all hospitalized CAP. Of
note, the average number of legionellosis cases reported
by Niagara Health annually from 2011 to 2015 was 6.
Public Health Ontario performed a thorough evaluation
of these cases and indicated that there were no epi-
demiological links.
Twelve (86 %) of the fourteen Legionnaires’ disease
cases were identified with a positive urinary Legionella
antigen assay. One case was tested negative with the urin-
ary Legionella antigen assay due to non-L. pneumophila
infection confirmed with BAL real-time PCR assay. One
case did not have a urinary Legionella antigen assay sent
but was tested positive for L. pneumophila with BAL real-
time PCR assay. In total, seven (50 %) cases were tested
positive with the real-time PCR assay, and three cases
(21 %) were culture-positive (Table 1).
Demographics, medical comorbidities and risk factors are
presented in Table 2. The majority (12 patients, 86 %) of
the patients had comorbidities, with hypertension, dyslipid-
emia, and diabetes mellitus occurring in more than half of
the cohort. In addition to the presence of comorbidities,
the other major risk factors for Legionnaires’ disease in this
patient population included cigarette smoking (ten patients
[71 %]) and marijuana use (three patients [21 %]).
Clinical features
All 14 patients met systemic inflammatory response
syndrome criteria (Table 2). Twelve patients (86 %)
reported cough, with 50 % of the patients reporting
sputum production. Only a minority of patients pre-
sented with gastrointestinal symptoms. Confusion or a
change in mental status was present in 50 % of patients
at presentation.
Laboratory results were recorded for patients upon
presentation to the emergency department and are pro-
vided in Table 2. The most common laboratory abnor-
malities included an elevated leukocyte count (71 %),
elevated creatine kinase (50 %), hyponatremia (64 %),
elevated creatinine (64 %), elevated troponins (64 %),
and elevated liver enzymes (86 %). At the time of admis-
sion, only five patients (36 %) had bilateral infiltrates
visualized by chest x-ray.
The Pneumonia Severity Index (PSI) is a prediction
rule for prognosis that objectively stratifies patients with
CAP into quintiles of risk for short-term mortality on
the basis of 20 demographic and clinical variables rou-
tinely available at presentation. It has been validated
with data on >50,000 patients [33]. PSI scores were
calculated for each patient on admission (Table 3). The
majority of patients had a PSI of grade IV or above (ten
patients [71 %]).
Treatment, clinical complications and outcomes
The treatment, clinical complications, and outcomes of
the 14 patients with Legionnaires’ disease are summa-
rized in Table 3. Delayed administration of appropriate
antibiotic treatment with azithromycin or a fluoroquino-
lone (defined as not commencing antibiotics within 24 h
after the patient presented to the emergency depart-
ment) occurred in four patients. Eleven patients (79 %)
required admission to an ICU or a step-down unit. The
step-down unit in Niagara Health is a monitored unit
with a nurse-to-patient ratio of 1:2. All patients undergo
continuous cardiac monitoring and oximetry. This unit
manages patients who require noninvasive ventilatory
support and vasopressive support. Nine patients (64 %)
required mechanical ventilation, eight patients (57 %) re-
quired vasopressive support, and five patients (36 %) re-
quired renal replacement therapy. Clinical improvement
was protracted, with average ICU/step-down unit and
hospital lengths of stay of 13 and 16 days, respectively.
The hospital mortality rate was 21 % in this cohort.
Discussion
Legionnaires’ disease is a life-threatening condition that re-
quires prompt diagnosis and treatment. In this study, 64 %
of the reported cases occurred from June to August
2013. This is typical in temperate climates in the north-
ern hemisphere because the causative organism
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multiplies effectively in warm aquatic environments [2].
The median age of our patient cohort was 58 years,
which was less than what was published by Public
Health Ontario in 2011. Indeed, most of our patients
were <65 years of age (71 %), despite the fact that the
incidence of Legionnaires’ disease is reported to in-
crease with age [34]. This suggests that age may not be
a prominent characteristic for community-acquired
Legionnaires’ disease that is not associated with a point
source outbreak. Tobacco use is a well-documented risk
factor for Legionnaires’ disease [35], and our results
showed that cigarette smoking was a common feature in
our cohort of patients with Legionnaires’ disease. A less-
established risk factor for Legionnaires’ disease is cannabis
use. Results published by Nguyen et al. provided support
for an increased risk of Legionnaires’ disease in cannabis
smokers and suggested that this risk may be cumulative
with the risk incurred through tobacco use [36]. Interest-
ingly, in our cohort of patients with Legionnaires’ disease,
we found that three patients were both cannabis and
cigarette smokers.
Clinical recognition of Legionnaires’ disease is made dif-
ficult by the fact that patient presentation is often incon-
sistent with the clinical presentation documented in the
literature [2, 6]. Our data suggest that the diagnosis of
Legionnaires’ disease on the basis of clinical presentation
is unreliable.
Our results demonstrate that Legionnaires’ disease
results in severe pneumonia, as reflected by the high PSI
score and impacts on multiple organ systems rather than
being confined solely to the pulmonary system. The
multisystem nature of Legionnaires’ disease likely con-
tributes in part to the acute presentation of patients with
Legionnaire’s disease and the need for more intensive
management. With almost three-fourths of the patients
requiring admission to an ICU, almost two-thirds requir-
ing mechanical ventilation for an average of 9 days, and
over half requiring vasopressors, these results certainly
corroborate the data suggesting that the clinical manifes-
tations of Legionnaires’ disease are often more severe
than those of pneumonias caused by other infectious
agents [37].
Chest x-rays are one of the first diagnostic tests
performed on patients upon arrival in the emergency de-
partment. As with much of the presentation thus far, the
chest x-ray of patients with Legionnaires’ disease does
not possess any distinguishing features that would guide
diagnosis. The initial chest x-ray of just over one-third
of the patients demonstrated bilateral airspace disease;
the remaining two-thirds had unilateral findings. However,
six of the patients with unilateral findings on their initial
x-ray progressed to bilateral findings on follow-up images.
This progression of radiographic findings throughout hos-
pital admission prior to noting improvements has been
documented in the literature [6]. There were not any iden-
tifiable patterns in terms of proclivity for specific lobes or
features of lung involvement.
The most common method of Legionnaires’ disease
diagnosis was urinary Legionella antigen testing (92.9 %).
In our case series, of the 13 patients tested for urinary
Legionella antigen, 12 had a positive result. One of the
patients was infected by non-L. pneumophila Legionella
(diagnosed with BAL real-time PCR). As such, other
forms of diagnostic tests, including real-time PCR and
culture of sputum or BAL samples, are indicated if there
is a suspicion of Legionnaires’ disease and the result of
Table 1 Legionnaires’ disease diagnostic tests
Patient Urinary antigen test BAL real-time PCR BAL culture Sputum real-time PCR Sputum culture
1 Positive Negative Negative N/A N/A
2 N/A Positive Negative N/A N/A
3 Positive N/A N/A N/A N/A
4 Positive N/A N/A N/A N/A
5 Positive N/A N/A N/A N/A
6 Positive Positive Negative N/A N/A
7 Positive N/A N/A N/A N/A
8 Positive N/A N/A Positive Positive
9 Positive N/A N/A Positive Positive
10 Negative Positivea Negative N/A N/A
11 Positive N/A N/A Positive Negative
12 Positive N/A N/A N/A N/A
13 Positive N/A N/A N/A N/A
14 Positive Positive Positive N/A N/A
N/A Not applicable, BAL bronchoalveolar lavage, PCR polymerase chain reaction
aNon-Legionella pneumophila
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urinary Legionella antigen testing is negative [38]. It has
been suggested that a combination of urinary Legionella
antigen testing and real-time PCR is the best initial ap-
proach to ensure detection of all Legionella infections
and obtain results within a time frame capable of influ-
encing management [39]. This is corroborated in our
case series by the fact that one of the diagnoses would
have been missed had a real-time PCR of a BAL sample
not been done concurrently with urinary Legionella anti-
gen testing.
Delay in initiating appropriate antibiotic therapy is
known to be a poor prognostic factor in patients in-
fected by Legionella [39]. In our case series, four patients
had delayed initiation of antibiotic therapy with a fluoro-
quinolone or azithromycin. Although none of these pa-
tients died as a result of this delay in diagnosis and
treatment, two of these patients had hospital stays that
exceeded 25 days, and both of them required mechanical
ventilation and vasopressor support. One patient also
required dialysis throughout the admission, and three
patients required admission to the ICU. As such, it is
Table 2 Characteristics, comorbidities, risk factors, symptoms,
and vital signs
Variable Value
Age, years, median (IQR) 57 (47–66)
Male sex, n (%) 8 (57)




Coronary artery disease 3 (21)
Chronic lung disease 2 (14)
Chronic renal insufficiency 4 (29)
Immunosuppression 2 (14)
Cigarette smoking 10 (71)
Cannabis use 3 (21)
Symptoms, n (%)
Productive cough 7 (50)
Nonproductive cough 5 (36)
Shortness of breath 12 (86)
Pleuritic chest pain 3 (21)
Nonpleuritic chest pain 2 (14)
Diarrhea 4 (29)
Nausea/vomiting 3 (21)
Abdominal pain 4 (29)





Vital signs at triage, n (%)
Heart rate >90 beats per minute 10 (71)
Respiratory rate >20 breaths per minute 12 (93)
Systolic blood pressure <90 mmHg 1 (7)
Temperature <36 °C or >38 °C 10 (71)
Laboratory values (normal range), mean ± SD
Leukocytes (4.0–11.0), ×109/L 14.9 ± 4.9
Creatinine (46–92), μmol/L 286 ± 460
Sodium (135–145), mmol/L 133 ± 4
Phosphate (0.8–1.45), mmol/L 1.48 ± 1.98
Creatine kinase (40–200), U/L 1914 ± 2728
Bilirubin (3–22), μmol/L 13 ± 11
Aspartate aminotransferase (10–40), U/L 77 ± 63
Alanine aminotransferase (5–68), U/L 54 ± 27
Alkaline phosphatase (50–135), U/L 90 ± 31
Troponin (<0.045), μg/L 0.66 ± 1.43
Lactate (0.4–2.1), mmol/L 2.3 ± 1.3
Table 2 Characteristics, comorbidities, risk factors, symptoms,
and vital signs (Continued)
Arterial pH (7.35–7.45) 7.32 ± 0.14
Distribution of infiltrates on initial chest x-ray, n (%)
Unilateral 9 (64)
Bilateral 5 (36)
Table 3 Treatment, clinical complications, and outcomes
Variable Value
Pneumonia Severity Index
Score, mean ± SD 115 ± 45
Grade I, n (%) 1 (7)
Grade II, n (%) 0 (0)
Grade III, n (%) 3 (21)
Grade IV, n (%) 4 (29)
Grade V, n (%) 6 (43)
Delay in appropriate antimicrobial therapy, n (%) 4 (29)
Clinical complications, n (%)
Vasopressor requirement 8 (57)
Mechanical ventilation 9 (64)
Renal replacement therapy 5 (36)
ICU/step-down unit admission 11 (79)
Outcomes
Duration of mechanical ventilation, days, mean ± SD 9 ± 4
ICU/step-down unit length of stay, days, mean ± SD 13 ± 8
Hospital length of stay, days, mean ± SD 16 ± 10
Hospital mortality, n (%) 3 (21)
ICU Intensive care unit
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evident that, while a delay in treatment did not result in
a higher mortality rate, it has the potential to worsen
disease severity and result in a need for more intensive
management. Of note, the three patients who died were
older (aged 66, 74, and 81 years, respectively). One
patient was immunosuppressed on methotrexate and
prednisone for rheumatoid arthritis; two patients had a
significant cardiac history and diabetes; and two patients
were cigarette smokers.
A study conducted in Switzerland demonstrated that
patients infected with atypical pathogens, including
Legionella, had clinical instability refractory to treatment
with a β-lactam and required the addition of a macrolide
to the treatment regimen [40]. The same study demon-
strated that patients with more severe pneumonias bene-
fited from a combination therapy as opposed to β-lactam
monotherapy. As such, it is suggested that the initial treat-
ment approach for patients presenting with severe CAP
(those with a PSI category IV pneumonia) include a macro-
lide or fluoroquinolone with effectiveness in treating
Legionella rather than waiting for laboratory confirmation
of infection [40]. Our study suggests that patients present-
ing with severe multisystem disease during the summer or
early autumn requiring admission to the ICU need atypical
coverage with a macrolide or fluoroquinolone prior to
laboratory confirmation. Atypical coverage should also be
added to a treatment regimen when there is no improve-
ment noted with β-lactam treatment.
Our study was limited by the fact that our data collection
was dependent on the reporting and diagnostic tests
ordered by other healthcare professionals. As a result,
full patient histories and laboratory values could not be
obtained for each patient. A prospective study would
overcome this limitation. Last, we do not have a control
group with non-Legionella CAP to assess risk factors
for Legionnaires’ disease.
Conclusions
Legionnaires’ disease should be considered during the late
spring and summer months in patients with a history of
tobacco use and various comorbidities presenting with
severe, multisystem disease characterized by shortness of
breath; abnormal vital signs; and laboratory derangements,
including hyponatremia, elevated creatine kinase, and
evidence of organ dysfunction. Legionnaires’ disease
should be diagnosed with a combination of urinary
Legionella antigen testing and Legionella real-time PCR
if available. Antibiotic therapy with a macrolide or a
fluoroquinolone should be initiated for severe CAP
prior to laboratory confirmation of diagnosis, especially
when a clinical suspicion exists.
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